Molecular Biomarkers in Cancer.
Sarhadi VK, Armengol G. · 2022
Read Molecular Biomarkers in Cancer. by Sarhadi VK, Armengol G. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9331210.txt.
Introduction
Sarhadi and Armengol review molecular biomarkers in cancer. A biomarker is any measurable molecular sign of cancer risk, presence, or outcome. Signs can hide in genes, gene activity, or proteins. Samples may come from tumor tissue or, more gently, from blood, saliva, urine, or stool.
The review sorts biomarker types and the tools that detect them. Uses span risk checks, screening, diagnosis, outlook, and therapy choice. Precision oncology depends on them, since targeted drugs work only in patients with matching mutations. New tests read tumor DNA floating in blood or tiny vesicles called exosomes. The authors say better sensitivity and accuracy are still needed. Faster detection tech keeps widening what can be measured.
Catalog record
| CREATOR | Sarhadi VK, Armengol G. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 118 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |